Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
[BACKGROUND] Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains l
- 표본수 (n) 31
- p-value P < .001
- p-value P = .0015
APA
Zhou B, Ma Z, et al. (2026). Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.. The oncologist, 31(2). https://doi.org/10.1093/oncolo/oyaf439
MLA
Zhou B, et al.. "Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.." The oncologist, vol. 31, no. 2, 2026.
PMID
41495001
Abstract
[BACKGROUND] Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT.
[PATIENTS AND METHODS] This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).
[RESULTS] Baseline characteristics showed similar distributions between the two groups. SBRT + Sin + Bev group showed a significant increase in both median OS (18.9 vs 9.3 months, P < .001), median PFS (9.1 vs 4.7 months, P = .0015), and ORR (64.6% vs 26.3%, P = .031) compared to Sin + Bev group. TRAEs in SBRT + Sin + Bev group were mostly manageable and acceptable compared to Sin + Bev group. Multivariate analysis confirmed that SBRT + Sin + Bev was an independent prognostic factor for better OS (P < .001) and better PFS (P < .001).
[CONCLUSION] SBRT combined with sintilimab plus bevacizumab appears to improve treatment efficacy and demonstrates a favorable safety and feasibility profile for HCC with PVTT.
[PATIENTS AND METHODS] This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).
[RESULTS] Baseline characteristics showed similar distributions between the two groups. SBRT + Sin + Bev group showed a significant increase in both median OS (18.9 vs 9.3 months, P < .001), median PFS (9.1 vs 4.7 months, P = .0015), and ORR (64.6% vs 26.3%, P = .031) compared to Sin + Bev group. TRAEs in SBRT + Sin + Bev group were mostly manageable and acceptable compared to Sin + Bev group. Multivariate analysis confirmed that SBRT + Sin + Bev was an independent prognostic factor for better OS (P < .001) and better PFS (P < .001).
[CONCLUSION] SBRT combined with sintilimab plus bevacizumab appears to improve treatment efficacy and demonstrates a favorable safety and feasibility profile for HCC with PVTT.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Bevacizumab; Liver Neoplasms; Male; Female; Antibodies, Monoclonal, Humanized; Middle Aged; Retrospective Studies; Radiosurgery; Portal Vein; Aged; Antineoplastic Combined Chemotherapy Protocols; Adult; Treatment Outcome; Venous Thrombosis
같은 제1저자의 인용 많은 논문 (5)
- NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression.
- Exosomal MYD88 isolated from 4T1 breast cancer cells using microfluidic chips promotes depressive-like behavior through neural remodeling in the mPFC.
- Spontaneous rupture of hepatic metastasis as the initial presentation of gastric hepatoid adenocarcinoma: a rare case report and literature review.
- Single-cell and bulk transcriptomic profiling of metabolism-related lncRNAs reveals tumor heterogeneity and prognostic markers in non-small cell lung cancer.
- Mitochondrial-Disrupting Antimicrobial Peptide Nanoparticles as Precise Pyroptosis Inducers for Breast Cancer Immunotherapy.